{"entity":{"id":"nct06367088","kind":"trial","name":"Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of cadonilimab in triple-negative breast cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.","summary":"Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT06367088 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 27 participants, started 2024-05-01 and due to reach its primary completion in 2026-04-30. Interventions recorded: Cadonilimab. Conditions listed: Triple-negative Breast Cancer; Cadonilimab. Triple-negative eligibility wording from the registry: \"* Recurrent or metastatic TNBC patients;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06367088","url":"https://clinicaltrials.gov/study/NCT06367088"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cadonilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06367088","phase":"2","setting":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","enrolled":27,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06367088/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}